Therapy Trends KOL Insight: Hepatocellular Carcinoma
KOLs anticipate Tecentriq and Avastin combination will become the standard of care for Hepatocellular Carcinoma (HCC) though COVID-19 may hinder the speed of its introduction. What role do KOLs see for current market leader Bayer's Nexavar and will the company's Stirvaga also come under pressure in the second-line setting? US and European KOLs critically assess the prospects of launched and pipeline therapies.
|Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.|
Key questions answered
- Why are KOLs not positive about the prospects for AVEO Oncology and AstraZeneca's Fotivda/Imfinzi combination?
- What safety issues do KOLs identify that may limit the potential of checkpoint inhibitors and their combinations such as Keytruda, Opdivo and Yervoy/Opdivo?
- In what settings and combination do KOLs see value for Exelixis/Ipsen's Cabometyx?
- Do KOLs see a future for Cure and Sure Biotech's tumour-derived heat shock protein Gp96 vaccine in HCC?
Examples of Therapies Covered
Partial List of Participating KOLs
|We engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.|
|Our-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.|
|Our reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.|
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.
Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.